Guggenheim Cuts InflaRx (NASDAQ:IFRX) Price Target to $14.00

InflaRx (NASDAQ:IFRX) had its target price reduced by stock analysts at Guggenheim from $22.00 to $14.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Several other research analysts have also weighed in on the stock. Leerink Partners reissued a “market perform” rating and set a $2.00 price objective (down from $5.00) on shares of InflaRx in a research note on Wednesday, December 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of InflaRx in a research report on Tuesday, December 30th. Finally, Raymond James Financial reaffirmed an “outperform” rating on shares of InflaRx in a research note on Wednesday, December 31st. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, InflaRx has an average rating of “Moderate Buy” and an average price target of $6.17.

InflaRx Stock Up 3.4%

NASDAQ:IFRX opened at $0.91 on Friday. InflaRx has a 12-month low of $0.71 and a 12-month high of $1.94. The stock’s fifty day simple moving average is $0.93 and its 200-day simple moving average is $1.15. The firm has a market capitalization of $61.06 million, a P/E ratio of -1.34 and a beta of 1.48.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.17) EPS for the quarter, meeting analysts’ consensus estimates of ($0.17). The company had revenue of ($0.04) million during the quarter, compared to the consensus estimate of $0.03 million. As a group, equities research analysts expect that InflaRx will post -1.04 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of IFRX. Cubist Systematic Strategies LLC boosted its holdings in shares of InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after buying an additional 7,616 shares during the period. HRT Financial LP bought a new position in InflaRx during the 4th quarter worth about $47,000. Concurrent Investment Advisors LLC increased its holdings in InflaRx by 56.9% during the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock worth $53,000 after purchasing an additional 19,200 shares in the last quarter. Insigneo Advisory Services LLC acquired a new stake in shares of InflaRx in the 4th quarter valued at about $61,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of InflaRx in the 4th quarter valued at about $104,000. Institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.